However, loss of p53 tumour-suppressor activity can also occur through amplification of MDM2. As MDM2 is a negative regulator of p53, this promotes p53 degradation and inhibits p53 tumour ...
In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.
Hosted on MSN25d
Scientists aim to repair or replace p53 to combat cancerMy colleagues and I are studying two other closely related proteins that regulate p53 by marking it for destruction when it's no longer needed. These proteins, called MDM2 and MDMX, become ...
Western blot assays were performed to identify the presence of p53, phospho-p53, and murine double minute 2 (MDM2) isoforms in plasma samples. Densitometric analysis was used to determine the ...
The University of Melbourne and affiliated organizations presented the development of a new reporter mouse model designed to study the role of MDM2 and its transcriptional regulation in p53-mediated ...
Once everybody got on the same page, the community settled on a common name: p53. “The field looked at this and didn’t know what to make of it,” Levine said. “Because it wasn’t isolated like an ...
A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery and Interventional Science at University College London has systematically ...
It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results